Systematic, network-based characterization of therapeutic target inhibitors

Area of Science:

• Oncology
• Pharmacology
• Bioinformatics

Background:

• Many key tumor dependency proteins are poor pharmacological targets, lacking effective small-molecule inhibitors.
• Developing generalizable methods to prioritize tumor-specific protein activity inhibitors is crucial for translational cancer research.
• Conventional biochemical assays cannot systematically measure protein inhibitor effects across the proteome.

Purpose of the Study:

• To introduce OncoLead, a novel network-based computational approach for prioritizing candidate inhibitors against arbitrary therapeutic targets.
• To validate OncoLead's ability to identify both known and novel context-specific inhibitors for challenging targets like MYC and STAT3.
• To generate the first unbiased drug/regulator interaction map for cancer-relevant transcription factors.

Main Methods:

• Developed OncoLead, a network-based computational framework for inhibitor prioritization.
• Conducted in vitro and in vivo validation studies to assess OncoLead's predictions.
• Applied OncoLead to create a comprehensive map of drug-regulator interactions.

Main Results:

• OncoLead successfully recapitulated known inhibitors of cancer targets.
• The approach identified novel, context-specific inhibitors for difficult targets, including MYC and STAT3.
• Generated an unbiased interaction map of compounds modulating cancer-relevant transcription factor activity.

Conclusions:

• OncoLead provides a systematic and efficient method for prioritizing potential drug inhibitors against challenging cancer targets.
• The validated approach has significant translational value for precision medicine.
• The generated drug/regulator interaction map offers new insights into targeting transcription factors in cancer therapy.